News

Dosimetry devices for the ELIMAIA beamline have been developed by INFN-LNS

On February 9th, 2017 a crucial milestone for the development of the ELIMED dosimetry section of the ELIMAIA beamline was achieved by the INFN-LNS team. ELIMED is the beam transport and dosimetry section of the ELI Multidisciplinary  Applications for laser-Ion Acceleration (ELIMAIA) and represents a key technology for the entire ELI-Beamlines facility since it will enable users to perform pre-clinical research for future applications in cancer therapy, such as biological cell irradiation with short bunches of protons (not available at conventional facilities) accelerated by the HAPLS PW-class, 10 Hz laser.

The development of ELIMED is carried out at LNS-INFN laboratories in Catania (Italy) and is based on user requirements which have been gathered over the last 5 years at international level through the “ELIMED network” and through a series of workshops which have gathered users from several different disciplines (Physics, Biology, Medicine, Material Science, Engineering). The initial ELIMED initiative was launched in 2011 and subsequently formalized through a Memorandum-of-Understanding between IoP-ASCR (ELI) and INFN (LNS).

“ELIMAIA will be the first laser-based ion acceleration beamline entirely dedicated to users interested in investigating multidisciplinary applications with such non-conventional ion bunches and the ELIMED section will be crucial to deliver a well-controlled dose on user samples”, says Daniele Margarone leader of the Research Program for the implementation and operation of such beamline.

“Now we know that the dosimetry devices designed and realized for the future ELIMED beamline are perfectly suitable for future user purposes”, adds Pablo Cirrone who is leading the INFN-LNS team in charge of the design, development and delivery of the ELIMED beam transport and dosimetry line for pre-clinical and multidisciplinary applications.

The milestone which has been recently achieved at INFN-LNS showed that ELIMED will be able to perform absolute dosimetry measurements with a 3% accuracy and relative dosimetry with an uncertainty well below 3%.